Answers are grounded in this paper and cite their sources.
Lecanemab is an anti-amyloid-β protofibril antibody that slows cognitive decline in early Alzheimer's disease. Although amyloid-related imaging abnormalities (ARIA) occur predominantly early in treatment, reports of hemorrhagic events during extended treatment beyond 18 months remain limited. A 77-year-old woman completed a standard 1.5-year lecanemab regimen without ARIA on surveillance MRIs. The day after her 42nd infusion, she acutely developed confusion and incomprehensible speech. MRI revealed a 2.5-cm left parietal subcortical hemorrhage. This case highlights that symptomatic lobar hemorrhage may occur even during extended lecanemab therapy, underscoring the importance of continued safety monitoring during extended treatment.
No takes yet. Share an insight, caveat, or question.
Takahashi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: